Prometheus Biosciences sold Prometheus Biosciences to Merck as part of a acquisition on 2023-04-17.
Deal value was 108000000000 (source: Extracted) Seller position: 100% acquisition; Location: USA.
On the seller side, Latham & Watkins advised, led by Daniel Rees, Cheston Larson.
Generated by AI, original source from - Data is in progress
Paul, Weiss advises Merck on its US$10.8 billion acquisition of Prometheus Biosciences, with Latham & Watkins advising Prometheus Biosciences. | The Sponsor - The Sponsor
